The state of systemic immunity under the influence of polarized light and an immunomodulator in patients with HPV-associated cervicitis

Abstract

Background. According to current epidemiological studies, 94.9% of women suffering from sexually transmitted infections are diagnosed with the presence of human papillomavirus (HPV) DNA during the examination.

Aims. The aim of the study was to study the effect of combined exposure to blue monochromatic polarized incoherent light and polychromatic visible and infrared polarized light in combination with imihimod 5% cream for external use on the state of systemic immunity in patients with HPV-associated cervicitis.

Materials and methods. The study included 60 patients aged 20–35 years with an HPV-associated cervicitis with a history of at least 1 year, who were randomly divided into 3 groups: in the main group (n=20), course effects of blue monochromatic polarized incoherent light on the projection of the carotid arteries and polychromatic visible and infrared polarized light on the cervix in combination with imihimod 5% cream for external use (complex 1); in the comparison group (n=20) — exposure to polychromatic visible and infrared polarized light on the cervix in combination with imihimod cream for external use 5% (complex 2); in the control group (n=20) — a course of local exposure to the cervix with imihimod cream 5%. The data of the survey of 20 healthy women of the same age were taken as the values of the norm. The state of systemic immunity in patients with HPV-associated cervicitis before treatment and after the course was evaluated by the indicators of mature T-lymphocytes (CD3⁺), CD4⁺, CD8⁺, immunoregulatory index (IRI = CD4⁺/CD8⁺), CD16⁺ (natural killer cells) and CD20⁺ (B-mature lymphocytes) in peripheral blood.

Results. Before the start of treatment, the patients showed low levels of CD3⁺-lymphocytes and a decrease in the immunoregulatory index, which is the ratio of CD4⁺/CD8⁺ against the background of an increase in the relative content of CD16⁺ and CD20⁺, which indicates an imbalance in the cellular immunity. After the course of treatment, the most pronounced results were obtained under the influence of complex 1: a significant increase in the relative content of CD3⁺ and normalization of IRI against the background of a decrease to the reference values of the initially elevated levels of CD16 (%) and CD20 (%) in both the percentage and absolute ratio of these populations in peripheral blood. Patients treated with complex 2 also showed a positive, but less pronounced, trend towards an increase in CD3⁺ and IRI and a decrease in elevated CD16⁺ levels after the course of treatment. In the control group, there was no statistically significant difference between the indicators before and after treatment, and only a slight positive trend was observed for some of them.

Conclusion. The combined use of blue monochromatic polarized incoherent light on the projection of the carotid arteries in combination with polychromatic visible and infrared polarized light and imihimod 5% cream for external use on the cervix in patients with chronic cervicitis associated with papillomavirus infection, to a greater extent than the local use of polarized light in combination with imihimod 5%, has a pronounced immunocorrective effect on the cellular link of immunity.

Keywords

polychromatic polarized incoherent light / blue monochromatic polarized incoherent light / BIOPTRON light therapy / HPV-associated cervicitis / systemic immunity / imihimod

References

[1] Apolikhina IA. Papillomavirus infection of genitals in women Moscow: GEOTAR-Med; 2002. 111 р. (In Russ).

[2] Аполихина И.А. Папилломавирусная инфекция гениталий у женщин Москва: ГЭОТАР-Мед, 2002. 111 с.

[3] Caixeta RC, Ribeiro AA, Segatti KD, et al. Association between the human papillomavirus, bacterial vaginosis and cervicitis and the detection of abnormalities in cervical smears from teenage girls and young women. Diagn Cytopathol. 2015;43(10):780–785. doi: 10.1002/dc.23301

[4] Caixeta R.C., Ribeiro A.A., Segatti K.D., et al. Association between the human papillomavirus, bacterial vaginosis and cervicitis and the detection of abnormalities in cervical smears from teenage girls and young women // Diagn Cytopathol. 2015. Vol. 43, N 10. P. 780–785. doi: 10.1002/dc.23301

[5] Giannella L, Fodero C, Boselli F, et al. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015;18(4):617–623. doi: 10.3109/13697137.2015.1005592

[6] Giannella L., Fodero C., Boselli F., et al. Age-related changes in the diagnostic assessment of women with severe cervical lesions // Climacteric. 2015. Vol. 18, N 4. P. 617–623. doi: 10.3109/13697137.2015.1005592

[7] Gross G, Ikenberg H, Roussaki A, et al. Systemic treatment of condyloma acuminata with recombinant interferon-a 2a: low dose superior to high dose regime. Chemotherapy. 1986;32(6):537–541. doi: 10.1159/0002384642016

[8] Gross G., Ikenberg H., Roussaki A., et al. Systemic treatment of condyloma acuminata with recombinant interferon-α 2a: low dose superior to high dose regime // Chemotherapy. 1986. Vol. 32, N 6. Р. 537–541. doi: 10.1159/000238464

[9] Jayakumar NK. Cervicitis: how often is it non-specific. J Clin Diagn Res. 2015;9(3):EC11–12. doi: 10.7860/JCDR/2015/11594.5673

[10] Jayakumar N.K. Cervicitis: how often is it non-specific // J Clin Diagn Res. 2015. Vol. 9, N 3. Р. EC11–12. doi: 10.7860/JCDR/2015/11594.5673

[11] Tadzhieva VD, Trubnikova LI, Kulikova TK, et al. Application of phototherapy for treatment of placental insufficiency in pregnant women with diabetes mellitus in conditions of ecological trouble under blood serum morphology control. Human Ecology. 2012;(11):56–64. (In Russ).

[12] Таджиева В.Д., Трубникова Л.И., Куликова Т.К. и др. Применение фототерапии Биоптрон для лечения плацентарной недостаточности у беременных с сахарным диабетом в условиях экологического неблагополучия под контролем морфологии сыворотки крови // Экология человека. 2012. № 11. С. 56–64.

[13] Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016;4(1):58. doi: 10.1186/s40168-016-0203-0

[14] Mitra A., MacIntyre D.A., Marchesi J.R., et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? // Microbiome. 2016. Vol. 4, N 1. Р. 58. doi: 10.1186/s40168-016-0203-0

[15] Belotserkovtseva LD, Orudzhova EA, Shakhlamova MN, Pashkov VM. Comparative analysis of various methods of treatment of cervical intraepithelial neoplasia associated with HPV infection. Voprosy ginekologii, akusherstva i perinatologii. 2015;14(5):55–60. (In Russ).

[16] Белоцерковцева Л.Д., Оруджова Э.А., Шахламова М.Н., Пашков В.М. Сравнительный анализ различных методов лечения цервикальной интраэпителиальной неоплазии, ассоциированной с ВПЧ-инфекцией // Вопросы гинекологии, акушерства и перинатологии. 2015. Т. 14, № 5. С. 55–60.

[17] Epifanov VA, Korchazhkina NB. Medical rehabilitation in obstetrics and gynecology. Moscow: GEOTAR-Media; 2019. 504 p. (In Russ).

[18] Епифанов В.А., Корчажкина Н.Б. Медицинская реабилитация в акушерстве и гинекологии. Москва: ГЭОТАР-Медиа, 2019. 504 с.

[19] Semenov DM. Immunological abnormalities in women infected with human papilloma virus. Immunopathology, allergology, infectology. 2016;(2):67–73. (In Russ). doi: 10.14427/jipai.2016.2.67

[20] Семенов Д.М. Иммунологические изменения у женщин, инфицированных вирусом папилломы человека // Иммунопатология, аллергология, инфектология. 2016. № 2. С. 67–73. doi: 10.14427/jipai.2016.2.67

[21] Ermolenko DK, Isakov VA. Experience of using a new immunomodulatory drug “Galavit” in anti-relapse therapy of papillomavirus infection of the anogenital region. Immunology and Allergology. 2002;(2):155. (In Russ).

[22] Ермоленко Д.К., Исаков В.А. Опыт применения нового иммуномодулирующего препарата «Галавит» при противорецидивной терапии папилломавирусной инфекции аногенитальной области // Иммунология и аллергология. 2002. № 2. С. 155.

[23] Sokolovsky EV, Ignatovsky AV. Immunomodulatory therapy of papillomavirus infection. Voprosy ginekologii, akusherstva i perinatologii. 2015;4(4):27–30. (In Russ).

[24] Соколовский Е.В., Игнатовский А.В. Иммуномодулирующая терапия папилломавирусной инфекции // Вопросы гинекологии, акушерства и перинатологии. 2015. Т. 4, № 4. С. 27–30.

[25] Soloviev AM. Immunotherapy with isoprinosine as an adjuvant or independent method of treatment for patients with papilloma viral infection. Bulletin of Dermatology and Venereology. 2011;(5):146–151. (In Russ).

[26] Соловьев А.М. Иммунотерапия изопринозином как адъювантный или самостоятельный способ лечения больных папилломавирусной инфекцией // Вестник дерматологии и венерологии. 2011. № 5. C. 146–151.

[27] Zhevago NA, Samoilova KA, Obolenskaya KD. Changes in humoral immunity parameters after percutaneuos application of polychromatic visible and infrared light. Medical immunology. 2002;4(4-5):573–582. (In Russ).

[28] Жеваго Н.А., Самойлова К.А., Оболенская К.Д. Изменения некоторых параметров гуморального иммунитета при воздействии на поверхность тела человека полихроматического видимого и инфракрасного света // Медицинская иммунология. 2002. Т. 4, № 4-5. С. 573–582.

[29] Zhevago NA, Samoilova KA, Obolenskaya KD, Sokolov DI. Changes in cytokinc content in the peripheral blood of volunteers after their exposure to polychromatic visible and infrared liaht. Cytology. 2005;47(5):446–459. (In Russ).

[30] Жеваго Н.А., Самойлова К.А., Оболенская К.Д., Соколов Д.И. Изменение содержания цитокинов в периферической крови добровольцев после их облучения полихроматическим видимым и инфракрасным светом // Цитология. 2005. Т. 47, № 5. С. 446–459.

[31] Zubkovskaya EV. The use of polarized light in the treatment of cervical ectopia in nulliparous women [dissertation abstract]. Samara; 2009. 28 p. (In Russ).

[32] Зубковская Е.В. Применение поляризованного света в лечении эктопии шейки матки у нерожавших женщин: Автореф. дис. … канд. мед. наук. Самара, 2009. 28 с.

[33] Tsygankova OY, Kravchenko EN, Kuklina LV, et al. Prospects of using the combined preparation of colpocid in the treatment of cervical pathology associated with human papillomavirus. Mother and child in Kuzbass. 2018;(1):27–31. (In Russ).

[34] Цыганкова О.Ю., Кравченко Е.Н., Куклина Л.В., и др. Перспективы применения комбинированного препарата Кольпоцид в лечении патологии шейки матки, ассоциированной с вирусом папилломы человека // Мать и дитя в Кузбассе. 2018. № 1. С. 27–31.

RIGHTS & PERMISSIONS

Eco-Vector